Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | TAF1 | P21675 | 1/20 | 0.31 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.31 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.31 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.31 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27589630 | 0.80 | — | — | |
| SCHEMBL7617011 | 0.77 | MAPK8 (0.30) | — | |
| SCHEMBL7616758 | 0.77 | MAPK8 (0.33) | — | |
| SCHEMBL825561 | 0.77 | BRD4 (0.32) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL8988110 | 0.77 | MAPK8 (0.30) | — | |
| SCHEMBL4231524 | 0.77 | MAPK8 (0.30) | — | |
| SCHEMBL9443405 | 0.70 | CRBN (0.35) | BRD4TAF1BRPF1CREBBPCECR2 | |
| SCHEMBL7536015 | 0.68 | — | — | |
| SCHEMBL422814 | 0.67 | — | — | |
| SCHEMBL40761 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | claimed |
| CN-118116478-A | Nucleic acid-based data storage | 特韦斯特生物科学公司 | 2024-05-31 | — | — | CN | disclosed |
| CN-115181147-B | Preparation method of C4 '-trifluoromethylthio modified nucleoside and C4' -trifluoromethylthio modified nucleic acid | 南开大学 | 2024-04-02 | — | — | CN | disclosed |
| CN-110892485-B | Nucleic acid-based data storage | 特韦斯特生物科学公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2011132017-A1 | PYRIDO[3,4-D]PYRIMIDINYL ACETAMIDE DERIVATIVES AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010125469-A1 | PYRIMIDINEDIONE-FUSED HETEROCYCLIC COMPOUNDS AS TRPA1 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-11-04 | — | — | WO | disclosed |
| US-7534796-B2 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2009-05-19 | — | — | US | disclosed |
| WO-2006135763-A2 | INHIBITORS OF DNA REPAIR ENZYMES AND METHODS OF USE THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2006-12-21 | — | — | WO | disclosed |
| US-20060189617-A1 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189617-A1 | Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor | GNRHR, PRLHR, FSHR | CYP2A6 2206/4885BRD4 473/4885TAF1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.